|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Using MDA-MB-231 as a model breast cancer cell line, we provide evidence that PFN1 overexpression is associated with alterations in the expression of proteins that have been functionally linked to cell proliferation (FKPB1A, HDGF, MIF, PRDX1, TXNRD1, LGALS1, STMN1, LASP1, S100A11, S100A6), survival (HSPE1, HSPB1, HSPD1, HSPA5 and PPIA, YWHAZ, CFL1, NME1) and motility (CFL1, CORO1B, PFN2, PLS3, FLNA, FLNB, NME2, ARHGDIB).
|
25454514 |
2014 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Collectively, these data identify the essential mammary protein stathmin as protumorigenic and suggest it may serve as a potential therapeutic target in breast cancer.
|
30478213 |
2019 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In the present study we have examined Op18 protein expression by quantitative Western blot analysis in a panel of 151 semi-consecutive breast carcinoma samples.
|
10917544 |
2000 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Overexpression of the stathmin gene in a subset of human breast cancer.
|
9743287 |
1998 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The oncoprotein-18/stathmin 1 (STMN1), involved in cell progression and migration, is associated with clinical outcome in breast cancer.
|
25072257 |
2014 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
High STMN1 expression is a possible marker of breast cancer aggressiveness in association with proliferation, phenotype and cancer stem cell type.
|
28766688 |
2017 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Quantitative polymerase chain reaction and immunofluorescence by microscopic analysis of chimeras in vitro exhibited silencing of stathmin and survivin in the RB and breast cancer model.
|
26334953 |
2015 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53.
|
16909102 |
2007 |
|
Breast Carcinoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Silencing kinase-interacting stathmin gene enhances erlotinib sensitivity by inhibiting Ser¹⁰ p27 phosphorylation in epidermal growth factor receptor-expressing breast cancer.
|
21045138 |
2010 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Stathmin, encoded by the signature gene STMN1, was an accurate IHC marker of the signature and had prognostic significance in BC.
|
17452630 |
2007 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
STMN1 overexpression further identified subgroups of HCC patients with higher tumor recurrence and worse prognosis among HCC patients with early tumor stage (T1) or intermediate histological grades (G2 and G3), both of whom represent the majority of HCC patients receiving primary curative hepatectomy.
|
20232364 |
2010 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
On the other hand, miR-223 has been identified as one of the most down-regulated miRNAs in HCC, and its expression was shown to be negatively correlated with STMN1 expression.
|
28982915 |
2017 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The molecular mechanism of STMN1 upregulation in HCCs remained unclear.
|
22911364 |
2013 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This T<sub>3</sub>-mediated suppression of STMN1 supports the theory that T<sub>3</sub> plays an inhibitory role in HCC tumor growth, and suggests that the lack of normal THR function leads to elevated STMN1 expression and malignant growth.
|
27934948 |
2016 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Construction of a hepatocellular carcinoma cell line that stably expresses stathmin with a Ser25 phosphorylation site mutation.
|
26505358 |
2015 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Stathmin expression was up-regulated in HCC tissues, especially in metastatic HCC tissues, compared with normal liver, hepatitis and hepatic cirrhosis tissues.
|
20204289 |
2010 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A substantial reduction in STMN1 protein was further demonstrated upon restoration of miR-223 expression in HCC cell lines.
|
18555017 |
2008 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Approximately 90% of HCCs harbouring stathmin overexpression with concomitant p53 mutation or osteopontin overexpression exhibited vascular invasion, and hence the lowest 5-year survival, p = 0.00018 and p = 0.0009, respectively.
|
16739096 |
2006 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Inhibition of stathmin expression by gene-specific short interfering RNA (siRNA) was associated with a significant reduction of MT-dependent cellular functions such as tumor cell viability, proliferation, migration, and increased apoptosis in HCC cells.
|
17663418 |
2007 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The expressions of stathmin and EF1α gradually increased as multistep hepatocarcinogenesis progressed, showing the highest levels in HCC.
|
24885363 |
2014 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Further experiments demonstrated that STMN1 mediated intricate crosstalk between HCCs and hepatic stellate cells (HSCs) via triggering the HGF/MET signal pathway.
|
31785057 |
2020 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, our study suggested for the first time that STMN1 might be a major target for GA and GEA in combating HCC.
|
19086098 |
2009 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin.
|
17596871 |
2007 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Finally, murine and human HCC data indicate significant correlations of STMN1 expression with E2F1/TFPD1 and with KPNA2 expression and their association with poor prognosis in HCC patients.
|
31783876 |
2019 |
|
Malignant neoplasm of prostate
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
Stathmin expression and phosphorylation patterns were analyzed in mouse and human PCa cell lines as well as in human PCa tissue arrays.
|
17455228 |
2007 |